home / stock / immx / immx quote
Last: | $1.96 |
---|---|
Change Percent: | 0.47% |
Open: | $2.11 |
Close: | $1.96 |
High: | $2.12 |
Low: | $1.9 |
Volume: | 129,486 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.96 | $2.11 | $1.96 | $2.12 | $1.9 | 129,486 | 07-02-2024 |
$2.12 | $1.99 | $2.12 | $2.1799 | $1.97 | 109,706 | 07-01-2024 |
$1.98 | $2.13 | $1.98 | $2.1379 | $1.96 | 166,217 | 06-28-2024 |
$2.13 | $2.2 | $2.13 | $2.3 | $2.12 | 162,354 | 06-27-2024 |
$2.2 | $2.3 | $2.2 | $2.34 | $2.12 | 114,828 | 06-26-2024 |
$2.32 | $2.3 | $2.32 | $2.46 | $2.11 | 415,918 | 06-25-2024 |
$2.28 | $2.05 | $2.28 | $2.33 | $2.01 | 168,759 | 06-24-2024 |
$2.04 | $1.87 | $2.04 | $2.07 | $1.87 | 159,032 | 06-21-2024 |
$1.92 | $2 | $1.92 | $2.0445 | $1.89 | 84,904 | 06-20-2024 |
$2.01 | $2.04 | $2.01 | $2.17 | $2 | 140,144 | 06-19-2024 |
$2.01 | $2.04 | $2.01 | $2.17 | $2 | 140,144 | 06-18-2024 |
$2.05 | $2.05 | $2.05 | $2.25 | $2.03 | 130,852 | 06-17-2024 |
$2.06 | $2.01 | $2.06 | $2.26 | $2.01 | 309,041 | 06-14-2024 |
$2.08 | $2.12 | $2.08 | $2.17 | $2.011 | 60,196 | 06-13-2024 |
$2.14 | $2.1 | $2.14 | $2.3 | $2.01 | 154,759 | 06-12-2024 |
$2.04 | $2.07 | $2.04 | $2.08 | $2.02 | 34,268 | 06-11-2024 |
$2.07 | $2.03 | $2.07 | $2.09 | $2 | 52,140 | 06-10-2024 |
$2.03 | $2.01 | $2.03 | $2.15 | $2.01 | 73,189 | 06-07-2024 |
$2.06 | $2.05 | $2.06 | $2.115 | $1.9 | 138,093 | 06-06-2024 |
$2.08 | $1.88 | $2.08 | $2.18 | $1.8601 | 128,911 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient wi...